Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05652569Recruiting
Genomics-guided treatment plan for metastatic breast cancer
This trial tests a personalized treatment approach for people with metastatic (advanced spread) breast cancer using tumor testing. It may help guide doctors toward better-matched therapies based on genomic (DNA) information from your tumor.
AugsburgAges 14–100 - NCT05652348Recruiting
Predicting outcomes after heated chemotherapy for stomach or colon spread
This study tries to better predict how well patients do after heated chemotherapy placed in the abdomen during surgery for stomach or colon cancer that has spread to the lining of the abdomen. It may help doctors choose the best treatment plan and timing for future patients.
BerlinAges 18 years+ - NCT05667532Recruiting
Contrast mammogram screening for women with dense breasts
This study tests how well a special mammogram with contrast can help assess breast cancer risk in women with dense breast tissue. It may help improve screening planning, especially when standard mammograms are harder to read due to density.
Houston, TexasAges 30–75 - NCT05640791RecruitingPhase 2
Durvalumab with chemo before surgery for bile duct cancer
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age - NCT05632913Recruiting
Radiation seeds trial for recurring lung cancer in the chest
This trial tests a treatment that places tiny radiation “seeds” inside/near the chest tumor to treat recurrent lung cancer. It may help people whose cancer has come back and can be safely reached by the radiation device.
JerusalemAges 18 years+ - NCT05608252RecruitingPhase 1/Phase 2
Drug combination for advanced ER-positive, HER2-negative breast cancer
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Boston, MassachusettsAges 18 years+ - NCT05607108RecruitingPhase 2
Study drug for advanced lung cancer with a specific genetic change
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Basking Ridge, New JerseyAges 18 years+ - NCT05636111RecruitingPhase 1
Study drug lurbinectedin with weekly paclitaxel and bevacizumab
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
Houston, TexasAges 18 years+ - NCT05628376Recruiting
Tracking lung cancer evolution through treatment
This study follows people with lung cancer over time to see how the disease changes, especially during and after treatment. By collecting tumor samples and blood tests every few months, researchers hope to understand why some cancers come back or become resistant, and find better ways to treat them.
LondonAges 18 years+ - NCT05611034RecruitingPhase 1
Testing a lung treatment for colorectal cancer spread to lungs
This Phase 1 trial tests a targeted treatment delivered to the lungs for colorectal cancer that has spread to the lungs. It aims to see if the approach is safe and can reach lung tumors, especially when there are multiple lung lesions.
Toronto, OntarioAges 18–70 - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT05627219Recruiting
Training men to share prostate cancer genetics info
This study tests a program that trains men (especially African American men) to help others understand prostate cancer genetic counseling and testing. It may improve access to this information by using peer support and patient navigation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05588128Recruiting
Scan study for prostate cancer after PSA comes back
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
Bethesda, MarylandAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Birmingham, AlabamaAges Any age - NCT05562778Recruiting
Chatbot helps you complete hereditary cancer genetic risk testing
This study tests whether a chatbot can help people complete hereditary cancer genetic risk assessment before a gynecology new-patient visit. It may help you understand and organize next steps for genetic testing, if needed.
Brooklyn, New YorkAges 18 years+ - NCT05553782RecruitingEarly Phase 1
IMD device study for certain head and neck cancers
This early-phase study tests a new small device (placed through the skin) plus standard surgery to study head and neck cancers. It may help researchers understand how the device works and gather safety information for people who need definitive surgery for a measurable tumor.
Boston, MassachusettsAges 18 years+ - NCT05590624Recruiting
Mediterranean diet study for men on prostate cancer active surveillance
This trial studies how different controlled versions of a Mediterranean-style diet may affect prostate cancer-related metabolism in men choosing active surveillance. It may help participants understand whether diet changes influence markers linked to prostate cancer activity, while keeping them on a monitored care plan.
Cleveland, OhioAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT05590949Recruiting
Bone health study for breast cancer survivors off bone medication
This study looks at bone complications in women who have finished treatment with denosumab (a bone-strengthening drug) and aromatase inhibitors (hormone therapy for breast cancer). It aims to learn more about what happens to bones after stopping these medications, which may help guide future care.
Basking Ridge, New JerseyAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05587439Recruiting
Study of inherited genetic risk in lung and related cancers
This study looks for inherited (family-passed) genetic changes that may raise the risk of lung cancer and related thoracic cancers. It may help people and families understand their genetic risk by collecting health information and sometimes specimens from patients and relatives.
Boston, MassachusettsAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,892 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.